Edarbyclor Tablet
Product Images NDC 60631-412

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Edarbyclor (NDC 60631-412). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals), these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1.a (Edarbyclor 01)

A line graph depicting the percentage of patients achieving systolic blood pressure under 140 mmHg across different baseline systolic blood pressure levels (140 to 190 mmHg). The graph compares Edarbyclor 40/25 mg tablets, Azilsartan medoxomil 80 mg, and Chlorthalidone 25 mg, illustrating Edarbyclor's consistently higher efficacy across the range.*

FDA Label Image

Figure 1.b (Edarbyclor 02)

A line graph comparing the percentage of patients with systolic blood pressure below 130 mmHg at various baseline systolic blood pressures for Edarbyclor 40/25 mg, Chlorthalidone 25 mg, and Azilsartan medoxomil 80 mg. The x-axis shows baseline systolic BP (mmHg) and the y-axis shows the percentage of patients achieving systolic BP under 130 mmHg. Edarbyclor 40/25 mg consistently shows higher efficacy across baseline pressures.*

FDA Label Image

Figure 1.c (Edarbyclor 03)

A line graph comparing the percentage of subjects with diastolic blood pressure (BP) less than 90 mmHg against baseline diastolic BP (mmHg) for Edarbyclor 40/25 mg, Azilsartan medoxomil 80 mg, and Chlorthalidone 25 mg. The graph shows Edarbyclor maintaining a higher percentage below 90 mmHg across the baseline range compared to the individual components Azilsartan medoxomil and Chlorthalidone.*

FDA Label Image

Figure 1.d (Edarbyclor 04)

A line graph comparing the percentage of patients achieving diastolic blood pressure below 80 mmHg against baseline diastolic blood pressure (mmHg). It includes three curves representing Edarbyclor 40/25 mg, Azilsartan medoxomil 80 mg, and Chlorthalidone 25 mg, showing differential efficacy across baseline diastolic BP values.*

FDA Label Image

Chemical Structure (Edarbyclor 05)

Chemical structure of Azilsartan kamedoxomil, the active ingredient in Edarbyclor tablets. The diagram shows the molecular bonds and arrangement including potassium ion (K+), characteristic of this angiotensin II receptor blocker.*

FDA Label Image

Chemical Structure (Edarbyclor 06)

Chemical structure of the active ingredient Azilsartan kamedoxomil, showing the molecular arrangement including sulfonamide, hydroxyl, chloro, and other functional groups.*

FDA Label Image

Figure 2 (Edarbyclor 07)

A pharmacokinetic chart illustrating fold changes and 90% confidence intervals for Edarbyclor across various population subgroups including age, gender, race, renal impairment, hepatic impairment, and pediatric groups. The x-axis shows change relative to reference, and the chart provides dose adjustment recommendations, mostly indicating no dose adjustment for studied groups.*

FDA Label Image

Figure 3 (Edarbyclor 08)

A line graph depicting the mean change in mm Hg of a variable over 24 hours after dosing. The graph compares three groups: Azilsartan medoxomil 40 mg, Chlorthalidone 12.5 mg, and Edarbyclor 40/12.5 mg. The y-axis shows mean values ranging from 1 to -35 mm Hg, while the x-axis represents hours after dosing from 1 to 24.*

FDA Label Image

Principal Display Panel (40 mg/12.5 mg Tablet Bottle Label)

Label for Edarbyclor tablets containing 40 mg azilsartan medoxomil and 12.5 mg chlorthalidone. The oral prescription drug label shows 30 tablets, NDC 60631-412-30, manufactured for Arbor Pharmaceuticals, LLC and by Takeda in Osaka, Japan. Instructions include storage at 25°C with protection from moisture and light.*

FDA Label Image

Principal Display Panel (40 mg/25 mg Tablet Bottle Label)

Edarbyclor 40 mg/25 mg oral tablets label showing the product name with active ingredients azilsartan medoxomil and chlorthalidone. It displays the quantity of 30 tablets and instructs to dispense and store in the original container. The label includes dosage strength, storage conditions, manufacturer Takeda (Osaka, Japan), and labeler Arbor Pharmaceuticals LLC (Atlanta, GA). Tamper-evident seal warnings and usage instructions are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.